Intracranial Hemorrhage

In the AXIOMATIC-SSP trial, milvexian, a novel factor XIa inhibitor, was protective against ischemic stroke with no increased risk for intracranial hemorrhage compared with placebo in patients requiring secondary prevention.

Administration of low-dose IV tenecteplase in the 4.5 to 24 hours after stroke symptom onset seemed to be safe and effective in the reperfusion and recanalization of occluded large cerebral vessels, a speaker reported.

Anticoagulation with rivaroxaban for patients with atrial fibrillation aged 65 years or more was associated with greater risk for major ischemic and hemorrhagic events compared with apixaban, according to data published in JAMA.

Lumosa Therapeutics announced its novel agent for patients with acute ischemic stroke met the primary safety endpoint in a phase 2 trial.

In a meta-analysis, researchers observed that severe direct oral anticoagulant-related bleeding death was relatively frequent, despite treatment with reversal agents, and that achieving hemostasis greatly improved survival.

During endovascular therapy for large vessel occlusion stroke, more than three attempts at clot retrieval was associated with elevated risk for symptomatic intracranial hemorrhage, regardless of procedure time, researchers reported.

An adjustable clot retriever device for large vessel occlusion ischemic stroke was demonstrated to be both more effective and safer compared with prior data on other stent-retriever devices, a speaker reported.

Enlarged perivascular spaces within the basal ganglia represented a novel risk factor for intracranial hemorrhage among patients taking oral anticoagulants, according to a post hoc analysis of the CROMIS-2 (AF) study published in Neurology.

In the VOYAGER PAD trial, patients with symptomatic peripheral artery disease who underwent lower-extremity revascularization had a lower incidence of major adverse limb and CV events compared if treated with low-dose rivaroxaban twice daily plus aspirin, compared with aspirin only.

The use of oral anticoagulation was low and may not be safe or effective in patients with atrial fibrillation and end-stage renal disease, according to a retrospective study of a propensity-matched cohort published in the Journal of the American College of Cardiology.